Brief: Astellas Pharma Inc - Update On Izervay (Avacincaptad Pegol Intravitreal Solution) Supplemental New Drug Application
18/11/2024 23:01
Nov 19 (Reuters) - Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC - UPDATE ON IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL
SOLUTION) SUPPLEMENTAL NEW DRUG APPLICATION
Source text: ID:nTSwr80660
Further company coverage: 4503.T
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)